Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States

医学 回顾性队列研究 医疗保健 子宫内膜癌 癌症 队列 急诊医学 内科学 经济 经济增长
作者
Monica Kobayashi,Jamie Garside,Joehl Nguyen
出处
期刊:Journal of health economics and outcomes research 卷期号:10 (2) 被引量:2
标识
DOI:10.36469/001c.88419
摘要

Background: Endometrial cancer (EC) represents a substantial economic burden for patients in the United States. Patients with advanced or recurrent EC have a much poorer prognosis than patients with early-stage EC. Data on healthcare resource utilization (HCRU) and costs for patients with advanced or recurrent EC specifically are lacking. Objectives: To describe HCRU and costs associated with first-line (1L) therapy for commercially insured patients with advanced or recurrent EC in the United States. Methods: This was a retrospective cohort study of adult patients with advanced or recurrent EC using the MarketScan® database. Treatment characteristics, HCRU, and costs were assessed from the first claim in the patient record for 1L therapy for advanced or recurrent EC (index) until initiation of a new anti-cancer therapy, disenrollment from the database, or the end of data availability. Baseline demographics were determined during the 12 months before the patient’s index date. Results: A total of 7932 patients were eligible for inclusion. Overall, mean age at index was 61 years, most patients (77.3%) had received prior surgery for EC, and the most common 1L regimen was carboplatin/paclitaxel (59.1%). During the observation period, most patients had at least one healthcare visit (all-cause, 99.9%; EC-related, 82.8%), most commonly outpatient visits (all-cause, 91.4%; EC-related, 68.7%). The highest mean (SD) costs (US dollars) were for inpatient hospitalization for both all-cause and EC-related events ($8396 [$15,130] and $9436 [$16,784], respectively). Total costs were higher for patients with a diagnosis of metastasis at baseline than for those without a diagnosis of metastasis. Discussion: For patients with advanced or recurrent EC in the United States, 1L therapy is associated with considerable HCRU and economic burden. They are particularly high for patients with metastatic disease. Conclusions: This study highlights the need for new cost-effective treatments for patients with newly diagnosed advanced or recurrent EC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
汪汪汪发布了新的文献求助10
2秒前
2秒前
2秒前
Elin完成签到,获得积分10
2秒前
rui完成签到,获得积分20
3秒前
杀出个黎明应助fengyinhe采纳,获得10
3秒前
3秒前
小小完成签到,获得积分10
4秒前
Unifate发布了新的文献求助10
5秒前
5秒前
5秒前
苏继谙完成签到,获得积分10
6秒前
rui发布了新的文献求助10
6秒前
暮光微凉发布了新的文献求助10
6秒前
7秒前
7秒前
CipherSage应助xy采纳,获得10
8秒前
8秒前
11秒前
11秒前
11秒前
CY完成签到,获得积分10
12秒前
13秒前
13秒前
13秒前
zhu发布了新的文献求助10
14秒前
14秒前
邓飞飞发布了新的文献求助10
15秒前
Jinnnnn完成签到 ,获得积分10
19秒前
20秒前
种地小能手~完成签到,获得积分10
20秒前
S飞发布了新的文献求助30
20秒前
21秒前
21秒前
22秒前
冬虫夏草完成签到,获得积分10
22秒前
乐乐应助hihi采纳,获得10
22秒前
accept完成签到,获得积分10
22秒前
人言不足畏完成签到,获得积分10
22秒前
高分求助中
Continuum Thermodynamics and Material Modelling 2000
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
こんなに痛いのにどうして「なんでもない」と医者にいわれてしまうのでしょうか 510
いちばんやさしい生化学 500
The First Nuclear Era: The Life and Times of a Technological Fixer 500
岡本唐貴自伝的回想画集 500
A mandible of Pliosaurus brachyspondylus (Reptilia, Sauropterygia) from the Kimmeridgian of the Boulonnais (France) 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3680916
求助须知:如何正确求助?哪些是违规求助? 3233098
关于积分的说明 9806237
捐赠科研通 2944452
什么是DOI,文献DOI怎么找? 1614657
邀请新用户注册赠送积分活动 762274
科研通“疑难数据库(出版商)”最低求助积分说明 737328